Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Long-Term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma
  2. Long-Term Survival After Percutaneous Radiofrequency Ablation of Pathologically Proven RCC
  3. Exploration of the Relationships Between Tumor Mutation Burden With Immune Infiltrates in ccRCC
  4. Perioperative Detection of CTCs in Radical or Partial Nephrectomy for RCC
  5. ASCO GI 2020: Abstract Recommendations From Dr. Jun Gong
  6. Anxiety and Depression Are Not Associated With Inferior Outcomes Among Patients With ccRCC Undergoing Nephrectomy
  7. Improved Response and Survival With Cabozantinib in Patients With Advanced RCC Regardless of Age
  8. Transcriptomic Signatures Related to the Obesity Paradox in Patients With Clear Cell Renal Cell Carcinoma
  9. Renal Mass Biopsy in the Management of Kidney Cancer
  10. Novel Risk-Scoring System for Patients With mRCC Treated With Immune Checkpoint Inhibitors

Elsewhere

Recently Updated